XASX
BOD
Market cap2mUSD
Nov 23, Last price
0.02AUD
Name
Bod Science Ltd
Chart & Performance
P/E
16.43
P/S
1.28
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
14.43%
Rev. gr., 5y
-7.83%
Revenues
3m
+280.92%
Net income
259k
P
CFO
937k
P
Earnings
Oct 30, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bod Science Limited, founded in Double Bay, Australia in 2014, is a pharmaceutical innovator and product developer specializing in cannabis-derived solutions. Operating across Australia, the United Kingdom, the European Union, and the United States, the company's activities are structured into three key divisions: Medical, Over-The-Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. Its primary focus involves the development and manufacturing of consumer-oriented CBD and hemp products, as well as the creation and supply of therapeutic medicinal cannabis offerings for healthcare sectors. Beyond its cannabis-centric work, Bod Science also provides herbal remedies like Flexofytol, a clinically proven turmeric extract designed to enhance joint health, protect cartilage from aging, and mitigate inflammation associated with mild arthritis. Another product, Sedistress, is a passion flower extract formulated to ease symptoms of stress, anxiety, and sleep disturbances. The company adopted its current name, Bod Science Limited, in December 2022, having previously operated as Bod Australia Limited.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||